Section Arrow
BNTC.NASDAQ
- Benitec Biopharma
Quotes are at least 15-min delayed:2024/05/16 02:58 EDT
Last
 8.85
+0.42 (+4.98%)
Day High 
9.12 
Prev. Close
8.43 
1-M High
10.29 
Volume 
18.42K 
Bid
8.4
Ask
9.3
Day Low
8.42 
Open
8.59 
1-M Low
4.75 
Market Cap 
71.65M 
Currency USD 
P/E -- 
%Yield
10-SMA 8.58 
20-SMA 7.72 
50-SMA 6.24 
52-W High 10.29 
52-W Low 1.86 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-236.13/-0.37
Enterprise Value
71.93M
Balance Sheet
Book Value Per Share
1.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
75.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 02:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.